GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OSTO:ONCO) » Definitions » Valuation Rank

Oncopeptides AB (OSTO:ONCO) Valuation Rank


View and export this data going back to 2017. Start your Free Trial

What is Oncopeptides AB Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Oncopeptides AB Valuation Rank Related Terms

Thank you for viewing the detailed overview of Oncopeptides AB's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncopeptides AB (OSTO:ONCO) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncopeptides AB (OSTO:ONCO) » Definitions » Valuation Rank
Comparable Companies
OSTO:DMYD B OSTO:CANTA OSTO:XBRANE XSAT:CURAS OSTO:SYNACT OSTO:ITECH OSTO:INIT OSTO:IVACC OSTO:INDEX OSTO:KDEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
0RN4:UK OND:Germany
Address
Vastra Tradgardsgatan 15, Stockholm, SWE, SE-111 53
Website
https://www.oncopeptides.com
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate melflufen (Ygalo), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.